Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir

Part of paid clinical trials in Chula Vista, California.

Sponsor
Novo Nordisk A/S
Study ID
NCT00873223
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
  • insulin detemir — DRUG
    Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration

Study Details

This trial is conducted in the United States. The aim of this clinical trial is to investigate whether chronic liraglutide administration affects the mode of action (pharmacokinetics) of insulin detemir

Key Dates

Start date
Mar 31, 2009
Status verified
Jan 2017
Primary completion
Sep 30, 2009
Completion
Sep 30, 2009

Study Design

Enrollment
33 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: A

Primary Outcome Measure

Insulin detemir pharmacokinetics with and without liraglutide administration [ Time Frame: at approx. 12 weeks (including screening, washout and evaluation period) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Novo Nordisk Investigational SiteChula VistaCalifornia91911-

Find similar trials in Chula Vista, CA

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Novo Nordisk Investigational Site· Chula Vista, CA

Related Studies